We are live on !
Find out more
Eversept Partners Portfolio holdings
AUM
$1.93B
Turnover
41.06%
1-Year Est. Return
160.8%
This Fund
S&P 500
This Quarter Est. Return
+18.5%
1 Year Est. Return
+160.8%
3 Year Est. Return
+321.09%
5 Year Est. Return
+420.29%
10 Year Est. Return
–
AUM
$1.93B
AUM Growth
+$31.2M
(+1.6%)
Cap. Flow
+$169M
Cap. Flow % of AUM
Cap. Flow %
8.75%
Top 10 Holdings %
Top 10 Hldgs %
45.68%
Holding
151
New
31
Increased
40
Reduced
42
Closed
31
Avg Time Held
Equity + Options
1
year
Top 10 Avg Time Held
Equity + Options
0.8
years
Top 20 Avg Time Held
Equity + Options
1.2
years
Avg Time Held Equity only
1
year
Top 10 Avg Time Held Equity only
0.9
years
Top 20 Avg Time Held Equity only
1.1
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
The Ensign Group
ENSG
|
+$104M |
| 2 |
Encompass Health
EHC
|
+$86.2M |
| 3 |
CareTrust REIT
CTRE
|
+$42.1M |
| 4 |
UnitedHealth
UNH
|
+$19M |
| 5 |
Insmed
INSM
|
+$18.1M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
GSK
GSK
|
+$68.9M |
| 2 |
Natera
NTRA
|
+$44.5M |
| 3 |
Healthpeak Properties
DOC
|
+$32.5M |
| 4 |
Avantor
AVTR
|
+$23.3M |
| 5 |
Qiagen
QGEN
|
+$20.3M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 89.53% |
| 2 | Real Estate | 5.59% |
| 3 | Miscellaneous | 4.84% |
| 4 | Financials | 0.05% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
1
United Therapeutics
UTHR
$25.2B
| $156M | 8.09% |
287,668
+23,397
| +9% | +$13.2M |
2020 Q2
24 quarters
|
|
2
Abivax
ABVX
$7.68B
| $122M | 6.32% |
913,880
-20,543
| -2% | -$2.32M |
2025 Q3
3 quarters
|
|
|
3
Encompass Health
EHC
$12.2B
| $104M | 5.38% |
1,026,919
+832,815
| +429% | +$86.2M |
2025 Q4
2 quarters
|
|
|
4
The Ensign Group
ENSG
$10.2B
| $96.5M | 5.01% |
602,079
+587,318
| +3,979% | +$104M |
2026 Q1
1 quarter
|
|
5
Vera Therapeutics
VERA
$2.02B
| $94.9M | 4.93% |
2,212,770
+39,484
| +2% | +$1.47M |
2022 Q3
15 quarters
|
|
6
PUT
Invesco QQQ Trust
QQQ
$475B
| $72.6M | 3.77% |
98,600
-140,100
| -59% | -$96.4M |
2023 Q1
13 quarters
|
|
7
Celldex Therapeutics
CLDX
$2.3B
| $66.5M | 3.45% |
1,785,941
-2,075
| -0.1% | -$67K |
2021 Q4
18 quarters
|
|
8
Syndax Pharmaceuticals
SNDX
$1.2B
| $61.2M | 3.17% |
2,798,210
-87,412
| -3% | -$1.82M |
2022 Q2
16 quarters
|
|
9
Brookdale Senior Living
BKD
$2.41B
| $54.6M | 2.84% |
3,396,470
-172,085
| -5% | -$2.34M |
2025 Q4
2 quarters
|
|
10
Ionis Pharmaceuticals
IONS
$7.13B
| $52.7M | 2.73% |
664,684
+32,584
| +5% | +$2.45M |
2021 Q2
20 quarters
|
|
|
11
Natera
NTRA
$58.2B
| $47.7M | 2.48% |
175,807
-208,906
| -54% | -$44.5M |
2022 Q2
16 quarters
|
|
12
Travere Therapeutics
TVTX
$4.72B
| $45.4M | 2.35% |
798,973
+256,363
| +47% | +$11.4M |
2024 Q1
9 quarters
|
|
|
13
CareTrust REIT
CTRE
$8.65B
| $43.3M | 2.24% |
+1,072,015
| New | +$42.1M |
2026 Q2
0 quarters
|
|
14
HCA Healthcare
HCA
$102B
| $38.3M | 1.99% |
98,252
+19,023
| +24% | +$8.04M |
2023 Q1
13 quarters
|
|
15
Vaxcyte
PCVX
$9.5B
| $36.6M | 1.9% |
629,952
-294,241
| -32% | -$16M |
2024 Q4
6 quarters
|
|
16
Liquidia Corp
LQDA
$3.82B
| $34.2M | 1.77% |
428,652
-248,740
| -37% | -$13.3M |
2021 Q1
21 quarters
|
|
17
Community Health Systems
CYH
$412M
| $26.3M | 1.36% |
7,864,575
-812,706
| -9% | -$2.39M |
2020 Q4
22 quarters
|
|
|
18
GSK
GSK
$102B
| $25.3M | 1.31% |
481,833
-1,303,342
| -73% | -$68.9M |
2018 Q1
33 quarters
|
|
19
Chemed
CHE
$6.7B
| $24.5M | 1.27% |
52,523
+21,466
| +69% | +$9.03M |
2026 Q1
1 quarter
|
|
20
Eli Lilly
LLY
$1.14T
| $24.1M | 1.25% |
20,116
+1,116
| +6% | +$1.14M |
2025 Q4
2 quarters
|
|
21
Geron
GERN
$720M
| $24M | 1.24% |
18,717,422
-117,461
| -0.6% | -$165K |
2025 Q2
4 quarters
|
|
22
Viking Therapeutics
VKTX
$3.1B
| $23.5M | 1.22% |
602,922
+363,812
| +152% | +$11.8M |
2026 Q1
1 quarter
|
|
23
Omega Healthcare
OHI
$14B
| $23.1M | 1.2% |
483,547
-102,133
| -17% | -$4.73M |
2026 Q1
1 quarter
|
|
24
Insulet
PODD
$10.3B
| $22.7M | 1.18% |
148,816
+5,270
| +4% | +$878K |
2025 Q3
3 quarters
|
|
25
Tenet Healthcare
THC
$21.6B
| $21.4M | 1.11% |
114,199
+84,687
| +287% | +$15.6M |
2026 Q1
1 quarter
|
|
Similar funds
Eversept Partners's Q2 2026 Portfolio in Review
As of Q2 2026, Eversept Partners held 151 positions worth $1.93B, up 1.6% from $1.9B the previous quarter. Its ten largest holdings account for 46% of the portfolio.
Eversept Partners deployed $169M of net new capital in Q2 2026, opening 31 new positions and adding to 40 existing holdings. Its largest new stake was CareTrust REIT: 1,072,015 shares worth $43.3M.
By sector, the portfolio is most concentrated in Healthcare at 90% of assets, up from 74% a quarter earlier, followed by Real Estate and Miscellaneous.
On the sell side, the largest reduction was GSK, an estimated $68.9M trimmed.
- Eversept Partners's largest Q2 2026 buy was CareTrust REIT: 1,072,015 shares worth $43.3M.
- Eversept Partners added most to The Ensign Group in Q2 2026, an estimated $104M increase.
- Eversept Partners's biggest Q2 2026 reduction was GSK, cutting an estimated $68.9M.
- Eversept Partners fully exited Healthpeak Properties in Q2 2026, selling an estimated $32.5M.
- Eversept Partners's ten largest holdings make up 46% of its $1.93B portfolio in Q2 2026.
- Eversept Partners opened 31 new positions and closed 31 in Q2 2026.
- Eversept Partners's portfolio value rose 1.6% quarter-over-quarter to $1.93B.
Based on Eversept Partners's 13F filing for Q2 2026, filed 14 Aug 2026.